News
Learn from NIH’s Michael Salgaller on how to partner with NIH at the Seoul Bio Forum on June 22, 2026. This forum is intended to bring together South Korean biotech and pharma companies with U.S. investors, research institutions, and industry leaders. He will be discussing NIH as a premier

Klebsiella bacteria cause about 10 percent of all hospital-acquired infections in the United States. A carbapenem-resistant K. pneumoniae strain known as multilocus sequence type 258 (ST258) is one of the antibiotic-resistant organisms labeled an urgent threat by the Centers for Disease Control and

Chuvash polycythemia is a rare, inherited disorder that is endemic to the Chuvash Republic of Russia, though it does occur in other parts of the world. NIH studies rare diseases not only to help the people who have them, but also to gain insight into gene functions that may benefit people with more

Maryland Technology Development Corporation (TEDCO) and the National Cancer Institute (NCI) Technology Transfer Center (TTC) entered into a Partnership Intermediary Agreement to support their mutual interests: facilitate the development and licensing of NCI technologies and support collaborative